Cheplapharm Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CHEPLAPHARM, and when can generic versions of CHEPLAPHARM drugs launch?
CHEPLAPHARM has thirteen approved drugs.
There are two US patents protecting CHEPLAPHARM drugs.
There are thirty-two patent family members on CHEPLAPHARM drugs in thirty-one countries and twenty-eight supplementary protection certificates in thirteen countries.
Summary for Cheplapharm
| International Patents: | 32 |
| US Patents: | 2 |
| Tradenames: | 12 |
| Ingredients: | 10 |
| NDAs: | 13 |
Drugs and US Patents for Cheplapharm
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cheplapharm | ZYPREXA | olanzapine | TABLET;ORAL | 020592-006 | Sep 9, 1997 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Cheplapharm | CYTOVENE | ganciclovir sodium | INJECTABLE;INJECTION | 019661-001 | Jun 23, 1989 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Cheplapharm | ZYPREXA RELPREVV | olanzapine pamoate | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 022173-003 | Dec 11, 2009 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
| Cheplapharm | DROXIA | hydroxyurea | CAPSULE;ORAL | 016295-003 | Feb 25, 1998 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Cheplapharm | VALCYTE | valganciclovir hydrochloride | FOR SOLUTION;ORAL | 022257-001 | Aug 28, 2009 | AB | RX | Yes | Yes | 9,642,911 | ⤷ Sign Up | Y | ⤷ Sign Up | ||
| Cheplapharm | ZYPREXA ZYDIS | olanzapine | TABLET, ORALLY DISINTEGRATING;ORAL | 021086-004 | Apr 6, 2000 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Cheplapharm | KLONOPIN | clonazepam | TABLET;ORAL | 017533-001 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Cheplapharm
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Cheplapharm | ZYPREXA | olanzapine | TABLET;ORAL | 020592-004 | Sep 30, 1996 | 5,605,897*PED | ⤷ Sign Up |
| Cheplapharm | KLONOPIN | clonazepam | TABLET;ORAL | 017533-002 | Approved Prior to Jan 1, 1982 | 4,316,897 | ⤷ Sign Up |
| Cheplapharm | ZYPREXA ZYDIS | olanzapine | TABLET, ORALLY DISINTEGRATING;ORAL | 021086-004 | Apr 6, 2000 | 5,817,656 | ⤷ Sign Up |
| Cheplapharm | ZYPREXA | olanzapine | TABLET;ORAL | 020592-004 | Sep 30, 1996 | 5,817,657*PED | ⤷ Sign Up |
| Cheplapharm | ZYPREXA | olanzapine | TABLET;ORAL | 020592-003 | Sep 30, 1996 | 5,605,897*PED | ⤷ Sign Up |
| Cheplapharm | CYTOVENE | ganciclovir sodium | INJECTABLE;INJECTION | 019661-001 | Jun 23, 1989 | 4,507,305 | ⤷ Sign Up |
| Cheplapharm | ZYPREXA | olanzapine | TABLET;ORAL | 020592-003 | Sep 30, 1996 | 5,736,541*PED | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for CHEPLAPHARM drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 450 mg | ➤ Subscribe | 2005-12-27 |
| ➤ Subscribe | Tablets | 150 mg and 500 mg | ➤ Subscribe | 2008-11-10 |
| ➤ Subscribe | For Oral Solution | 50 mg/mL | ➤ Subscribe | 2011-03-21 |
International Patents for Cheplapharm Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Poland | 2101733 | ⤷ Sign Up |
| Chile | 2007003564 | ⤷ Sign Up |
| Cyprus | 1113468 | ⤷ Sign Up |
| Australia | 2007332640 | ⤷ Sign Up |
| World Intellectual Property Organization (WIPO) | 2008071573 | ⤷ Sign Up |
| Canada | 2671470 | ⤷ Sign Up |
| Spain | 2391912 | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Cheplapharm Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0617614 | SPC/GB01/014 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: ALITRETINOIN; REGISTERED: UK EU/1/00/149/001 20001018 |
| 1304992 | 92401 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: CLINDAMYCINE(EN TANT QUE PHOPSHATE DE CLINDAMYCINE)ET TRETINOINE |
| 0129748 | 98C0042 | Belgium | ⤷ Sign Up | PRODUCT NAME: ORLISTAT; REGISTRATION NO/DATE: EU/1/98/071/001 19980729 |
| 0454436 | SPC/GB96/058 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: OLANZAPINE OPTIONALLY IN THE FORM OF AN ACID ADDITION SALT; REGISTERED: UK EU/1/96/022/001 19960927; UK EU/1/96/022/002 19960927; UK EU/1/96/022/003 19960927; UK EU/1/96/022/004 19960927; UK EU/1/96/022/005 19960927; UK EU/1/96/022/006 19960927; UK EU/1/96/022/007 19960927; UK EU/1/96/022/008 19960927; UK EU/1/96/022/009 19960927; UK EU/1/96/022/010 19960927 |
| 0694547 | SPC/GB02/027 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: 2-(2-AMINO-1,6-DIHYDRO-6-OXO-PURIN-9-YL)-METHOXY-3-HYDROXY-1-PROPANYL-L-VALINATE HYDROCHLORIDE (VALGANCICLOVIR HYDROCHLORIDE); REGISTERED: NL RVG 25992 20010920; UK PL 00031/0599 20020425 |
| 0694547 | 2002/028 | Ireland | ⤷ Sign Up | PRODUCT NAME: VALGANCICLOVIR (2-(2-AMINO-1,6-DIHYDRO-6-OXO-PURIN-9-YL)- METHOXY-3-HYDROXY-1-PROPANYL-L-VALINATE) AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; NAT REGISTRATION NO/DATE: 50/150/1 20020913; FIRST REGISTRATION NO/DATE: NL 25992 20010920; PAEDIATRIC INVESTIGATION PLAN: P/0220/2013 |
| 0694547 | C300071 | Netherlands | ⤷ Sign Up | PRODUCT NAME: VALGANCICLOVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: RVG 25992 20010920 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
